Zobrazeno 1 - 10 of 245 pro vyhledávání: '"Kvarnhammar AM"'
1
Akademický článek
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Autor: Rosen DB; Ascendis Pharma Inc, Redwood City, California, USA drn@ascendispharma.com., Kvarnhammar AM; Ascendis Pharma A/S, Hellerup, Denmark., Laufer B; Ascendis Pharma GmbH, Heidelberg, Germany., Knappe T; Ascendis Pharma GmbH, Heidelberg, Germany., Karlsson JJ; Ascendis Pharma A/S, Hellerup, Denmark., Hong E; Ascendis Pharma Inc, Redwood City, California, USA., Lee YC; Ascendis Pharma Inc, Redwood City, California, USA., Thakar D; Ascendis Pharma Inc, Redwood City, California, USA., Zúñiga LA; Ascendis Pharma Inc, Redwood City, California, USA., Bang K; Ascendis Pharma Inc, Redwood City, California, USA., Sabharwal SS; Ascendis Pharma Inc, Redwood City, California, USA., Uppal K; Ascendis Pharma Inc, Redwood City, California, USA., Olling JD; Ascendis Pharma A/S, Hellerup, Denmark., Kjaergaard K; Ascendis Pharma A/S, Hellerup, Denmark., Kurpiers T; Ascendis Pharma GmbH, Heidelberg, Germany., Schnabel M; Ascendis Pharma GmbH, Heidelberg, Germany., Reich D; Ascendis Pharma GmbH, Heidelberg, Germany., Glock P; Ascendis Pharma GmbH, Heidelberg, Germany., Zettler J; Ascendis Pharma GmbH, Heidelberg, Germany., Krusch M; Ascendis Pharma GmbH, Heidelberg, Germany., Bernhard A; Ascendis Pharma GmbH, Heidelberg, Germany., Heinig S; Ascendis Pharma GmbH, Heidelberg, Germany., Konjik V; Ascendis Pharma GmbH, Heidelberg, Germany., Wegge T; Ascendis Pharma GmbH, Heidelberg, Germany., Hehn Y; Ascendis Pharma GmbH, Heidelberg, Germany., Killian S; Ascendis Pharma GmbH, Heidelberg, Germany., Viet L; Ascendis Pharma GmbH, Heidelberg, Germany., Runz J; Ascendis Pharma GmbH, Heidelberg, Germany., Faltinger F; Ascendis Pharma GmbH, Heidelberg, Germany., Tabrizi M; Ascendis Pharma Inc, Redwood City, California, USA., Abel KL; Ascendis Pharma A/S, Hellerup, Denmark., Breinholt VM; Ascendis Pharma A/S, Hellerup, Denmark., Singel SM; Ascendis Pharma Inc, Palo Alto, California, USA., Sprogøe K; Ascendis Pharma A/S, Hellerup, Denmark., Punnonen J; Ascendis Pharma Inc, Redwood City, California, USA.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
Zobrazit plný text záznamu
2
Akademický článek
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Autor: Kvarnhammar AM; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden. amk@alligatorbioscience.com., Veitonmäki N; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Hägerbrand K; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Dahlman A; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Smith KE; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Fritzell S; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., von Schantz L; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Thagesson M; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Werchau D; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Smedenfors K; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Johansson M; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Rosén A; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Åberg I; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Winnerstam M; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Nyblom E; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Barchan K; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Furebring C; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Norlén P; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden., Ellmark P; Alligator Bioscience AB, Medicon Village, Scheelevägen 2, 223 81, Lund, Sweden.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Apr 11; Vol. 7 (1), pp. 103. Date of Electronic Publication: 2019 Apr 11.
Zobrazit plný text záznamu
3
Akademický článek
Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.
Autor: Cao, Lei-Ming1 (AUTHOR), Yu, Yi-Fu1 (AUTHOR), Li, Zi-Zhan1 (AUTHOR), Zhong, Nian-Nian1 (AUTHOR), Wang, Guang-Rui1 (AUTHOR), Xiao, Yao1 (AUTHOR), Liu, Bing1,2 (AUTHOR), Wu, Qiu-Ji3 (AUTHOR) wuqiuji@126.com, Feng, Chun4 (AUTHOR) fcjoyji@163.com, Bu, Lin-Lin1,2 (AUTHOR) lin-lin.bu@whu.edu.cn
Publikováno v: Journal of Nanobiotechnology. 6/3/2024, Vol. 22 Issue 1, p1-14. 14p.
Zobrazit plný text záznamu
4
Akademický článek
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Autor: Farhangnia, Pooya1,2,3,4 (AUTHOR), Khorramdelazad, Hossein5 (AUTHOR), Nickho, Hamid2,3 (AUTHOR), Delbandi, Ali-Akbar1,2,3 (AUTHOR) Delbandi.ak@Iums.ac.ir
Publikováno v: Journal of Hematology & Oncology. 6/4/2024, Vol. 17 Issue 1, p1-66. 66p.
Zobrazit plný text záznamu
5
Akademický článek
Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.
Autor: Schultz HS; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Reedtz-Runge SL; NCD Project Management, Global Research, Novo Nordisk A/S, Måløv, Denmark., Bäckström BT; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Lamberth K; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Pedersen CR; Immunogenicity Assessment, Global Research, Novo Nordisk A/S, Måløv, Denmark., Kvarnhammar AM; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark.
Publikováno v: PloS one [PLoS One] 2017 May 31; Vol. 12 (5), pp. e0178544. Date of Electronic Publication: 2017 May 31 (Print Publication: 2017).
Zobrazit plný text záznamu
6
Akademický článek
Activation of RIG-I signaling in the early stage of Paragonimus proliferus infection causes lung injury via type I immune response in rat.
Autor: Qing-Qing Wang1, Guo-Zhong Zhou2, Kun-Li Wu1, Yong-Rui Yang1, Hong-Juan Li1, Jie Ding1, Xing Liu1, Chong-Xi Li1, Lu Zhang3, Sheng-Hao Li1 doctorlee3h@163.com, Rui-Xian Zhang4 zhangrx2005@163.com
Publikováno v: Journal of Infection in Developing Countries. Mar2024, Vol. 18 Issue 3, p464-472. 9p.
Zobrazit plný text záznamu
7
Akademický článek
In Silico Comparative Expression Analyses of Pattern Recognition Receptors in Human Eosinophil Cell Lines and Primary Eosinophils.
Autor: Celik, Zulal1, Barutcu, Edanur1, Ozcelebi, Yagmur1, Sarac, Elif Yaprak1, Ciraci, Ceren1 ciracic@itu.edu.tr
Publikováno v: Turkish Journal of Immunology. dec2023, Vol. 11 Issue 3, p106-116. 11p.
Zobrazit plný text záznamu
8
Akademický článek
The Acari Hypothesis, V: deciphering allergenicity.
Autor: Retzinger, Andrew C., Retzinger, Gregory S.
Publikováno v: Frontiers in Allergy; 2024, p1-9, 9p
Zobrazit plný text záznamu
10
Akademický článek
LEAP-2, LL-37 and RNase7 in tonsillar tissue: downregulated expression in seasonal allergic rhinitis.
Autor: Bogefors J; Laboratory of Clinical and Experimental Allergy Research, Department of Otorhinolaryngology, Skånes University Hospital, Lund University, Malmö, Sweden., Kvarnhammar AM, Millrud CR, Georén SK, Cardell LO
Publikováno v: Pathogens and disease [Pathog Dis] 2014 Oct; Vol. 72 (1), pp. 55-60. Date of Electronic Publication: 2014 Jun 12.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje